Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Ablynx, Novo Nordisk sign drug discovery deal
January 2016
SHARING OPTIONS:

GHENT, Belgium—An exclusive global collaboration and licensing agreement is now underway between Abylnx and Novo Nordisk for the discovery and development of novel multispecific Nanobody drug candidates in an undisclosed disease area, with an option to expand the agreement to include a second program. Novo Nordisk will pay Ablynx an upfront license fee of €5 million (approximately $5.4 million) as well as up to €4 million (approximately $4.3 million) in research funding in the initial three-year research term of the collaboration. Should Novo Nordisk elect to exercise its option to a second program, it will pay Ablynx an exercise fee of €4 million. Ablynx also stands to receive development, regulatory and commercial milestone payments of up to €182 million (approximately $197.2 million) per program, plus tiered royalties on annual net sales. Novo Nordisk will assume responsibility for the development, manufacturing and commercialization of any products resulting from this collaboration.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.